Incannex Receives Ethics Approval for Bioequivalence/Bioavailability Clinical Trial for IHL-42X, the Company’s Proprietary Drug for Treatment of Obstructive Sleep Apnoea (‘OSA’)
July 06, 2023 08:42 ET
|
Incannex Healthcare
Highlights: Incannex has received approval from Bellberry Human Research Ethics Committee (‘HREC’) to commence the bioavailability/bioequivalence (‘BA/BE’) clinical trial to assess the...
Incannex Appoints Principal Investigators for IHL-42X Phase 2/3 Clinical Trial
June 16, 2023 08:00 ET
|
Incannex Healthcare
MELBOURNE, Australia, June 16, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing unique...
Incannex Company Presentation – Results from Phase 1 Clinical Trial to Assess Proprietary IHL-675A
May 03, 2023 07:30 ET
|
Incannex Healthcare
MELBOURNE, Australia, May 03, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Ltd (Nasdaq: IXHL) (ASX: IHL) (‘Incannex’ or ‘the Company’) is pleased to announce a company presentation containing data...
Incannex Appoints QPS to Advance CannQuit-N™ (Nicotine), CannQuit-O™ (Opioid) and Renecann™ Products in the USA and EU
April 14, 2023 07:30 ET
|
Incannex Healthcare
MELBOURNE, Australia, April 14, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Ltd (Nasdaq: IXHL) (ASX: IHL) (‘Incannex’ or ‘the Company’) a pharmaceutical company developing proprietary medicinal...
IGC to be Featured in Feb. 10 Radius Research Investor Webinar
February 08, 2023 08:30 ET
|
INDIA GLOBALIZATION CAPITAL INC.
POTOMAC, Md., Feb. 08, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- India Globalization Capital, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today announces that Ram Mukunda, CEO, and Claudia...
No Longer Just CBD - Ananda Professional Re-Writes the Category With Its New Condition-Driven Minor Cannabinoid Range
February 06, 2023 10:00 ET
|
Ananda Professional
GEORGETOWN, Ky., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Ananda Professional's multimillion-dollar research program continues to lead the way in identifying novel ways to leverage cannabinoids for the...
22nd Century Group (XXII) Acquires RX Pharmatech Ltd, Greatly Strengthening UK and EU Market Position
January 24, 2023 09:20 ET
|
22nd Century Group, Inc
Immediately Accretive Addition to the Hemp/Cannabis Business with Positive EBITDA 1,276 Novel Food Applications for Cannabinoid Products to Accelerate Growth in the U.K. and EU Food and...
Pii Congratulates Skye Bioscience for First-in-Human Phase 1 Trial of Proprietary Cannabinoid Derivative and Nanoemulsion Formulation Designed to Potentially Treat Glaucoma.
January 24, 2023 08:00 ET
|
Pharmaceutics International Inc.
Hunt Valley, MD, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Pharmaceutics International, Inc. (Pii), a contract development and manufacturing organization (CDMO), proudly celebrates a first-in-human Phase I...
22nd Century Group (XXII) Announces Filing of U.S. DMF (Drug Master File) for CBD API; New Global Sales, Marketing and Distribution Agreement with Transo-Pharm for Cannabinoid APIs
January 23, 2023 09:20 ET
|
22nd Century Group, Inc
BUFFALO, N.Y., Jan. 23, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis...
IGC Receives No Objection Letter from Health Canada
January 04, 2023 08:00 ET
|
INDIA GLOBALIZATION CAPITAL INC.
POTOMAC, Md., Jan. 04, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- India Globalization Capital, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today announces it has received a no objection...